Extraordinary growth in global VC financing of microbiome companies in 2020!

While the investment activity from 2017 to 2019 was relatively stable, ranging from EUR 273m to EUR 283m, a significant increase in global VC financing of microbiome companies in 2020 is observable. The volume increased by 73% to EUR 488m. This was mainly caused by a higher number of large deals. The average deal volume from 2017 to 2019 amounted to EUR 11m compared to an average deal volume of EUR 20m in 2020. The largest deal in 2020 was the Series D financing of Finch Therapeutics Group in the amount of EUR 76m. In 2021, only EUR 91m have been raised so far with only two deals greater than EUR 15m.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: